# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001104659-24-054167
Filing Date
2024-04-29
Accepted
2024-04-29 17:10:27
Documents
4
Period of Report
2024-06-12

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEF 14A | tm243000d1_def14a.htm | DEF 14A | 421967
2 | GRAPHIC | tm2412801d1_ex99-1img001.jpg | GRAPHIC | 16440
3 | GRAPHIC | tm243000d1_def14aimg001.jpg | GRAPHIC | 283802
4 | GRAPHIC | tm243000d1_def14aimg002.jpg | GRAPHIC | 384808
| Complete submission text file | 0001104659-24-054167.txt |  | 1335050

Mailing Address 101 LINDENWOOD DRIVE, SUITE 225 MALVERN PA 19355
Business Address 101 LINDENWOOD DRIVE, SUITE 225 MALVERN PA 19355 484-875-3192
Annovis Bio, Inc. (Filer) CIK: 0001477845 (see all company filings)

EIN.: 262540421 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-39202 | Film No.: 24892577
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)